Journal of Neurology Neurosurgery and Psychiatry

Article	Citations
091 The East London Parkinson’s disease project – engaging a diverse population in research	135
175 A case series of anti-HMGCR immune mediated necrotizing myopathy: the West Midlands data	118
102 Levodopa and melanoma what do clinicians think?	103
117 Who is the culprit – the virus or the anti-virus?	98
226  Reduced synaptic density in progressive supranuclear palsy and corticobasal syndrome, revealed by [11C]UCB-J PET	92
Haemorrhagic myelitis as a manifestation of MOG antibody-associated disease	84
35 Processing speed (PS) improvement in alcohol related brain damage (ARBD)	82
Navigating the presymptomatic frontier in genetic ALS and FTD	77
086 Long-term efficacy of fremanezumab in migraine patients with inadequate response to prior preventive medication classes	74
094  Measuring neutralising antibodies (NAbs) to interferon-beta (IFNB) for multiple sclerosis (MS): a neglected practice?	74
099  Safety and effectiveness of dimethyl fumarate in multiple sclerosis patients treated over 5 years	73
005  Infusion associated reactions in ocrelizumab-treated multiple sclerosis patients	69
122  Neurological manifestations of haemophagocytic lymphohistiocytosis	68
White matter hyperintensities and brain microbleeds in ataxia-telangiectasia: the Cambridge cohort	64
102  The cost of misdiagnosis in POEMS syndrome	64
001  Machine learning accurately determines the population prevalence of Alzheimer’s disease based on microbiome profile	61
010  Safety and efficacy of long-term dimethyl fumarate treatment	58
201  Management of an unusual presentation of spontaneous intracranial hypotension (SIH)	56
184  Right data, right care	54
L-arginine and mitochondrial encephalomyopathy, lactic acidosis and stroke- like episodes (MELAS): a systematic review	53
238  Cogniton and mood disorder in cervical dystonia	53
West is best – a strongman with numb feet	52
164  Progressive multifocal leukoencephalopathy (PML) following autologous periph- eral blood stem cell transplantation for multiple myeloma	52
12 A pilot investigation of interoceptive accuracy, awareness, and sensibility in functional neurological disorder	50
091  CIDP mimic in a patient with HIV; An unusual presentation of POEMS syndrome	50

Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts	48
059 Cannabidiol in refractory adult epilepsies: broadening the Lennox-Gastaut phenotype?	48
003  Neuroanatomical signatures of genetic risk for Alzheimer’s disease in healthy adults	47
143  Catastrophising cognitions in patients with psychogenic non-epileptic seizures compared to patients with epilepsy	46
114  Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease	46
Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning	45
Neural (re)organisation of language and memory: implications for neuroplasticity and cognition	44
101 Motor and non-motor features of prodromal PD	44
Sodium valproate is associated with cortical thinning of disease-specific areas in juvenile myoclonic epilepsy	44
High frequency ofHTRA1ANDABCC6mutations in Japanese patients with adult-onset cerebral small vessel disease	43
Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis	43
Improved naming in patients with Broca’s aphasia with tDCS	41
DNA methylation profiling in central nervous system tumours	40
Environmental risk scores of persistent organic pollutants associate with higher ALS risk and shorter survival in a new Michigan case/control cohort	40
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis	40
Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis	40
006  Seizure focus prediction from seizure semiology: data-driven cortical probabilis- tic heatmaps from 4643 patients	39
Characterising ALS disease progression according to El Escorial and Gold Coast criteria	39
Early treatment of type II SMA slows rate of progression of scoliosis	39
Late-onset epilepsy predicts future stroke: a systematic review and meta-analysis	38
096  Maintenance IVIg safe prescribing – audit of proforma and traffic light risk assessment system in NHNN	38
039  Cerebral venous sinus thrombosis and COVID-19: causation or coincidence?	35
161  Two-centre audit of cannabidiol use in adults with Dravet syndrome	35
084  Is there a positive correlation between single breath count and forced vital capacity?	35
259  A novel mutation of protein kinase C gamma associated with spinocerebellar ataxia type 14	35
Good outcomes after aggressive treatment of immune checkpoint inhibitor related myasthenia gravis: a case series	35
235  Assessing coding of diagnosis for atypical parkinsonian syndromes	35
016  Long-term disease stability in patients treated with cladribine tablets in CLARITY and CLARITY extension	35
239  New de novo mutation in CACNA1a gene leading to episodic ataxia type 2	34
Effects of VNS stimulation on electrocorticography in patients with dual neuro- stimulation devices	34
052 SKYLINE study design efficacy and safety of gantenerumab in participants at-risk for Alzheimer’s disease	32
005 A case of xanthomatous hypophysitis presenting as recurrent pituitary adenoma	32
40 Temporal discounting and male depression	32
178 Motor neurone disease and sociodemographic factors: a review	32
The Scottish Epilepsy Deaths Study Score (SEDS Score): a risk prediction model for epilepsy-related deaths	32
066 The Utility of 18-FDG PET imaging in the preoperative workup for epilepsy surgery	32
106 Critical ischaemia without infarction presenting as progressive hemichorea: a case study and literature review	31
Evaluation of MDS-PSP diagnostic criteria in a combined behavioural neurology and atypical parkinsonism service	31
110  UK multiple sclerosis service audit of 70 centres: MS-MDTs	31
009 Asymmetric peri-optic cerebrospinal fluid space distension in cluster headache	31
132 Adverse prognostic factors predicting disease modifying therapies in MS: a real- world cohort	31
055 Assessment of MACE cognitive screener using efficiency indexes	31
Genetics of inherited peripheral neuropathies and the next frontier: looking backwards to progress forwards	30
Association of obesity with mild traumatic brain injury symptoms, inflammatory profile, quality of life and functional outcomes: a TRACK-TBI Study	30
Dissociative seizures in the emergency room: room for improvement	29
Spinal cord motor neuron phenotypes and polygenic risk scores in sporadic amyotrophic lateral sclerosis: deciphering the disease pathology and therapeutic potential of ropinirole hydrochloride	29
Can brain signals and anatomy refine contact choice for deep brain stimulation in Parkinson’s disease?	29
Risk of stroke in multiple sclerosis and neuromyelitis optic spectrum disorder: a Nationwide cohort study in South Korea	28
Patients with symmetric Parkinson’s disease do poorly with subthalamic stimulation	28
Multicentre validation of a patient-reported outcome measure for functional movement disorders	28

Intravenous methylprednisolone as add-on induction therapy for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial	27
CIDP trials and tribulations	27
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with autoantibody-mediated neuroimmunology	27
Real-world experience of gene therapy with onasemnogene-abeparvovec (Zolgensma®) for patients with SMA-type1 in UK	26
What, when and how should the information about neurodegenerative disease risk in iRBD be communicated?	26
Comparative neural correlates of DBS and MRgFUS lesioning for tremor control in essential tremor	26
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry	26
021 Experience from a SARS-CoV2 neurology clinic at the national hospital of neurology and neurosurgery	26
Induction cyclophosphamide with maintenance immunosuppression in high-risk myasthenia gravis: long-term follow-up and safety profile	26
Influence of cardiorespiratory fitness and MRI measures of neuroinflammation on hippocampal volume in multiple sclerosis	26
028 Croydon neurology diagnostic coding of outpatients – the first year of experience	26
010 Trigeminal neuralgia in diffuse scleroderma – a rare but recognised association	25
142 Discordance between neurologists and people with MS on the presence and burden of cognitive impairment	25
099 Thrombotic and haemorrhagic complications associated with PLEX, reducing the risks	25
049 Hippocampal place cell dysfunction in an APP knock-in mouse model of Alzheimer’s disease	25
114 Pain and objectively measured cognitive performance in adults with multiple sclerosis: a systematic review	25
017  Year 1 performance of adveva® programme for patients taking cladribine tablets for relapsing-remitting multiple sclerosis	24
156 Association of locus of control with clinical and psychosocial aspects of living with multiple sclerosis	24
219  MRI monitoring in MS patients prescribed disease monitoring treatments in Kings College Hospital	24
171 Urinary P75: a novel biomarker for motor neuron disease?	24
222  DECISIve – DiagnosE using the Central veIn SIgn. A study comparing T2* MRI and lumbar puncture	24
244  Idiopathic anosmia with motor impairment – a unique prodrome of Parkinson’s?	23
258  A case of two brothers: should we look beyond a diagnosis of cerebral palsy?	23
199  Improving training in systems leadership management: a ‘Mini-Darzi’ approach	23
Biomarkers for brain injury and copper toxicity in Wilson’s disease: a diffusion tensor imaging study	23
026  Gene-environment interactions in multiple sclerosis: a UK Biobank study	22
024  CLARITY study: efficacy outcomes among patients receiving disease-modifying therapies prior to treatment with cladribine tablets	22
009  Abnormal blood-brain barrier permeability in progressive multiple sclerosis	22
046  Familial multiple sclerosis: a community-based epidemiology study in Cumbria	22
103  Virtual multiple sclerosis (MS) clinics during a global pandemic: the patients’ perspective	22
022  Functional genomics and transcriptomics further characterise and potentially improve diagnostic yield of hereditary ataxias	22
170  Did the atraumatic lumbar puncture needle campaign have any effect?	22
Quantification of muscle glycogen distribution in Pompe disease using 7 Tesla 13C NMR spectroscopy	21
Searches for biomarkers using highly sensitive techniques might reveal more about pathogenesis of a disease than provide clinically useful molecular tests	21
08 The economic cost of functional neurological disorders: a systematic review introduction	21
Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis	21
How effective is effective enough?	21
MRI lesions can often precede trigeminal neuralgia symptoms by years in multiple sclerosis	21
185 JEWELFISH: Safety, pharmacodynamic and exploratory efficacy data in non-naïve patients with SMA receiving risdiplam	21
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies	21
047 Clinicopathological characteristics impacting on survival in sporadic CJD: insights from an international autopsy-confirmed series	21
Mechanistic biology linking traumatic brain injury to multiple sclerosis susceptibility	21
Gene-specific impacts on brain architecture in genetic frontotemporal dementia	21
Validation of the hotspot for dorsolateral subthalamic nucleus targeting in deep brain stimulation surgery for Parkinson’s disease: a post hoc analysis of a randomised controlled trial	21
Serum level changes of the synaptic marker beta-synuclein in Alzheimer’s disease continuum and other dementias	21
Beyond antithrombotics: recent advances in pharmacological risk factor management for secondary stroke prevention	21
Cluster analysis showed long-term cognition can be predicted by looking at regional grey matter atrophy in the first two years of multiple sclerosis course	20
Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction	20
Insufficient sleep during adolescence and risk of multiple sclerosis: results from a Swedish case-control study	20
Evoked mid-frontal activity predicts cognitive dysfunction in Parkinson’s disease	20
058 Does prolonging duration of monitoring in epilepsy monitoring unit improve diagnostic yield?	19
Unhealthy traits and risk of Parkinson’s disease: a mendelian randomisation study	19
135  A national audit of service provision for patients with atypical parkinsonian syndrome	19
Attenuated heart-brain integration predicts functional non-epileptic seizures	19
091  Evaluation of remote assessments for multiple sclerosis in a real-world setting	19
124  Symptoms of post-traumatic stress disorder are common after being diagnosed with multiple sclerosis	19
A novel neurodegenerative disease with multi-system features	19
078  The future of outpatient appointments: do patients with epilepsy prefer remote consultations?	19
187  Variation in training: Results from a survey of UK neurology trainees	19
039  Disease modifying treatments and cancer monitoring in MS; the need for a nation-wide disease registry	18
126 The provision of anti-CD20 therapy in inflammatory demyelinating disorders of the CNS during SARS-CoV-2	18
080 IIH Life A prospective longitudinal cohort study of idiopathic intracranial hypertension	18
043  Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis	18
030  Hepatitis C reactivation with fingolimod treatment for relapsing-remitting multiple sclerosis (RRMS)	18
117  Sustained and rapid B-cell depletion with ofatumumab: population pharma- cokinetic B-cell modeling in relapsing MS patients	18
032  Improving access to inpatient ambulatory cardiac monitoring for acute stroke patients during the Covid-19 pandemic	18
128 Visuoperceptual deficits as measures of cognitive dysfunction in multiple sclerosis: a pilot study	18
25 ‘In a mist?’ – What is ‘brain fog’?	18
124  MEGAbIT – the role of OPM MEG in assessment and diagnosis In mTBI	18
225  A rare case of recurrent unsteadiness due to Miller Fisher syndrome	18
044  Analysis of urgent acute medicine and ward referrals to neurology at the district hospital	18
054 Baseline characteristics of the Phase III GRADUATE studies: investigating subcu- taneous gantenerumab in early AD	18
14 Saving Adam from the apple: using transcranial magnetic stimulation as a transdiagnostically relevant tool to decrease cue-reactivity	18
104  A case of natalizumab-related progressive multifocal leukoencephalopathy treated with pembrolizumab	18
Effects of immunotherapies and clinical outcomes in neurosarcoidosis : a retro- spective cohort study	18
11 The experience of hearing life altering medical news? Perspectives from health professionals	17
130  Does visual imagery vividness have a genetic basis? A genome-wide associa- tion study of 1019 individuals	17
Comparison of relative change with effect size metrics in Alzheimer’s disease clinical trials	17
IVIg-exposure and thromboembolic event risk: findings from the UK Biobank	17
Relapse activity after assisted reproductive technology treatments in women with multiple sclerosis: a nationwide cohort study in Denmark	17

125  Towards an optimal multiple sclerosis patient case-load for a full-time MSologist	17
Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort	17
Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study	17
Childbirth delivery mode and the risk of multiple sclerosis: a prospective population-based study	16
24 Intelligent sensing in ADHD trial (ISAT) – pilot study	16
Prescription opioid use in multiple sclerosis	16
Risk of secondary progressive multiple sclerosis after early worsening of disability	16
Investigating colour vision and its structural correlates 15 years following a first demyelinating event	16
Dynamics of choroid plexus volume is associated with the presence and development of fatigue in multiple sclerosis	16
Gene–environment interactions increase the risk of paediatric-onset multiple sclerosis associated with household chemical exposures	16
Choroid plexus enlargement in paediatric multiple sclerosis: clinical relevance and effect of sex	16
Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial	16
Peripheral hearing loss at age 70 predicts brain atrophy and associated cognitive change	16
Association between heavy alcohol consumption and cryptogenic ischaemic stroke in young adults: a case–control study	16
Can CANVAS due toRFC1biallelic expansions present with pure ataxia?	16
Ultrasensitive assay technology and fluid biomarkers for the evaluation of peripheral nerve disease	15
Stratifying quality of life outcome in subthalamic stimulation for Parkinson’s disease	15
064 Epilepsy and sociodemographic factors a review	15
044 At what resolution does the brain perform computations?	15
Epigenetic clocks in neurodegenerative diseases: a systematic review	15
Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis	15
Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon	15
Visuospatial dysfunction predicts dementia-first phenoconversion in isolated REM sleep behaviour disorder	15
056 Online assessment and monitoring of cognitive decline in neurological conditions	15
032 Supine hypertension and cardiovascular autonomic failure in patients with alpha-synucleinopathies	15
Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study	15
Brain neuronal and glial damage during acute COVID-19 infection in absence of clinical neurological manifestations	15
153 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS)	15
Therapeutic interventions increasing seizure risk in multiple sclerosis: resolving discordant meta-analyses	15
135  CMT with renal impairment: consider a dip	14
212  Preventing blindness for patients with optic disc swelling: improving care using transformative new technology	14
035  Diagnosis of secondary progressive multiple sclerosis in UK centres: results from the SPECTRUM project	14
003  Systemic inflammation, erythrocyte fragility and multiple sclerosis	14
242  A systematic review on the benefit of multidisciplinary care for patients with atypical parkinsonian syndromes	14
086  Thymectomy in myasthenia gravis – a review of 36 patients	14
011  Progressive myoclonic epilepsy due to rare mitochondrial ND6 mutation, m.14487T>C	14
070  What is seronegative neuromyelitis optica spectrum disorder?	14
Multiparametric quantitative MRI reveals progressive cortical damage over time in clinically stable relapsing-remitting MS	14
Genomic features specific to the human lineage are associated with neurological diseases and intelligence	14
030  Emerging parkinsonism in the PREDICT-PD cohort after 5-year follow-up	14
247  Unusual presentation to an emergency department	14
195  Delayed transfer of care (DToC) in neuroscience across South London: an insight through patient journeys	14
147 Siponimod preserves retinal thickness: findings from the EXPAND OCT substudy	14
Time to treat the climate and nature crisis as one indivisible global health emergency	14
074  Long-term effect of idebenone in reducing respiratory function decline in patients with Duchenne muscular dystrophy	14
8 Integrating dimensions of interoception in neuropsychiatry	13
Validation of MATCH score: a predictive tool for identification of patients with kelch-like protein-11 autoantibodies	13
204  Idiopathic intracranial hypertension in Wales: population characterisation, epidemiological trends and healthcare utilisation	13
Beware next-generation sequencing gene panels as the first-line genetic test in Charcot-Marie-Tooth disease	13
We hold these truths to be self-evident	13
Changes in the heartbeat-evoked potential are associated with functional seizures	13
Telomere length, in vivo Alzheimer’s disease pathologies and cognitive decline in older adults	13
37 The medicolegal challenges in neuropsychiatry: an evaluation of mental capacity and legal frameworks	13
Structural and functional alterations in the gustatory network underlie taste disturbances after lesional tremor therapy with MRgFUS	13
Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study	13
Do lower limb motor-evoked potentials predict walking outcomes post-stroke?	13
Incidence and prevalence of paediatric-onset multiple sclerosis in two Canadian provinces: a population-based study representing over half of Canada’s population	13
04 Should neuropsychiatry flow both ways? Neurology inreach into psychiatric hospital	13
30 Dissociation and its biological and clinical correlates in functional neurological disorder: a systematic review and meta-analysis	13
Short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA): a narrative review of interventional therapies	13
Elevated serum β-synuclein predicts cognitive decline and progression to dementia	13
163  Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures	13
Statin use and long-term risk of recurrent intracerebral haemorrhage: the MUCH-Italy	13
Clinical biomarker-based biological ageing and future risk of neurological disorders in the UK Biobank	12
023 Impact of pandemic on neurologists and neurology practice	12
Efgartigimod efficacy and safety in refractory myasthenia gravis: UK’s first real-world experience	12
Endovascular treatment for large-core ischaemic stroke: a meta-analysis of randomised controlled clinical trials	12
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, ph	12
Parallel Session 2: Neurodegeneration| Wed 18 May, 1115 – 1230|4 Novel complex motor behaviours in LGI1-autoantibody encephalitis	12
100 Antiphospholipid-related chorea	12
Epilepsy surgery outcomes and their determinants: a systematic review and individual patient data meta-analysis	12
Characterising alexithymia in individuals with functional motor disorders: a cross-sectional analysis of the Italian Registry of Functional Motor Disorders	12
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study	12
073 Fenfluramine exhibits disease-modifying effects in a mouse model of Dravet syndrome	12
Neurocognitive and psychiatric outcomes associated with postacute COVID-19 infection without severe medical complication: a meta-analysis	12
006 A novel approach in the management of functional neurological disorder in the hyper-acute setting	12
211  The prevalence and characteristics of multiple sclerosis-associated uveitis in UK biobank	11
179  Improving respiratory screening and NIV assessment in motor neuron disease	11
267  When investigating stroke is a waste of time	11
252  Whole exome sequencing in epilepsy: quality of reporting in literature	11
164 The role of MEG in assessment and diagnosis in mTBI	11
048  Postprandial somnolence in people with multiple sclerosis	11
138  Frey’s syndrome: a review of the aetiology and possible role of neurotrophic factors	11
205  Is it a brain tumour? Assessment on performance of the CNS two week wait pathway	11
079  The impact of the COVID-19 pandemic on the mental health of MND patients	11
42 Inhibition of personal memory retrieval in dissociative amnesia: a study of two cases	11
185  An assessment of perceived gender disparity in platform and poster presenters at ABN conferences	11
152  Automating the assessment of first seizure care pathways and clinical outcomes using electronic patient records	11
100  Making decisions and sharing information, the patient experience: the UK Multiple Sclerosis Register (UKMSR)	11
A roadmap to ALS prevention: strategies and priorities	10
152 AttackMS natalizumab for the treatment of people with inflammatory demyeli- nation suggestive of multiple sclerosis	10
Paramagnetic rim and core sign lesions in paediatric multiple sclerosis patients	10
Safety of breast feeding during rituximab treatment in multiple sclerosis	10
Head trauma results in manyfold increased risk of multiple sclerosis in genetically susceptible individuals	10
Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity	10